Publications by authors named "Taras V Ivanishin"
Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2.
Anna V Vakhrusheva Ekaterina A Romanovskaya-Romanko Marina A Stukova Maria M Sukhova Ksenia S Kuznetsova Taras V Ivanishin
Vaccines (Basel)
October 2024
Article Synopsis
- - SARS-CoV-2, responsible for COVID-19, is rapidly evolving, making the development of effective and safe vaccines critical for public health, with the Betuvax-CoV-2 vaccine showing promise in previous trials.
- - A study compared monovalent and bivalent vaccines' ability to neutralize different SARS-CoV-2 strains, revealing that while both types had strengths against certain variants, neither performed well against the Omicron BQ.1 strain at lower doses.
- - The research implies that vaccine effectiveness relies on matching the formulation to the circulating SARS-CoV-2 strain, and using a bivalent vaccine doesn't necessarily provide an advantage over a monovalent vaccine for a single variant.
Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.
Aleksandr V Kudriavtsev Anna V Vakhrusheva Nickolay A Kryuchkov Maria E Frolova Konstantin A Blagodatskikh Taras V Ivanishin
Vaccines (Basel)
February 2023
Unlabelled: COVID-19, being a life-threatening infection that evolves rapidly, remains a major public health concern calling for the development of vaccines with broad protection against different pathogenic strains and high immunogenicity. Aside from this, other concerns in mass immunization settings are also the scalability of production and relative affordability of the technology. In that regard, adjuvanted protein vaccines with particles mimicking the virus stand out among known vaccine technologies.
View Article and Find Full Text PDF